Evidence map›Paper›PMID 36575042›Full record

ArticleCell structure and function2023

A non-nucleotide agonist that binds covalently to cysteine residues of STING.

Kentaro Matsumoto, Shenwei Ni, Hiroyuki Arai, Takashi Toyama, Yoshiro Saito, Takehiro Suzuki, Naoshi Dohmae, Kojiro Mukai, Tomohiko Taguchi

Open access · goldAbstract read
In one paragraph

Article in Cell structure and function, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. STING Innate Immunity Signalling from the Golgi.Sub-cellular biochemistry · 2026
    Review
  4. Review
  5. Cell biological insights into human STING variants.Cell structure and function · 2025
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Kentaro MatsumotoLaboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University.
Shenwei NiDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo.
Hiroyuki AraiDepartment of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo.
Takashi ToyamaLaboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences, Tohoku University.
Yoshiro SaitoLaboratory of Molecular Biology and Metabolism, Graduate School of Pharmaceutical Sciences, Tohoku University.
Takehiro SuzukiBiomolecular Characterization Unit, Technology Platform Division, RIKEN Center for Sustainable Resource Science.
Naoshi DohmaeBiomolecular Characterization Unit, Technology Platform Division, RIKEN Center for Sustainable Resource Science.
Kojiro MukaiLaboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University.
Tomohiko TaguchiLaboratory of Organelle Pathophysiology, Department of Integrative Life Sciences, Graduate School of Life Sciences, Tohoku University.
Tohoku University · JPRIKEN Center for Sustainable Resource Science · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stimulator of interferon genes (STING) is an ER-localized transmembrane protein and the receptor for 2',3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP), which is a second messenger produced by cGAMP synthase (cGAS), a cytosolic double-stranded DNA sensor. The cGAS-STING pathway plays a critical role in the innate immune response to infection of a variety of DNA pathogens through the induction of the type I interferons. Pharmacological activation of STING is a promising therapeutic strategy for cancer, thus the development of potent and selective STING agonists has been pursued. Here we report that mouse STING can be activated by phenylarsine oxide (PAO), a membrane permeable trivalent arsenic compound that preferentially reacts with thiol group of cysteine residue (Cys). The activation of STING with PAO does not require cGAS or cGAMP. Mass spectrometric analysis of the peptides generated by trypsin and chymotrypsin digestion of STING identifies several PAO adducts, suggesting that PAO covalently binds to STING. Screening of STING variants with single Cys to serine residues (Ser) reveals that Cys88 and Cys291 are critical to the response to PAO. STING activation with PAO, as with cGAMP, requires the ER-to-Golgi traffic and palmitoylation of STING. Our results identify a non-nucleotide STING agonist that does not target the cGAMP-binding pocket, and demonstrate that Cys of STING can be a novel target for the development of STING agonist.Key words: STING agonist, cysteine modification, innate immunity, phenylarsine oxide.

Indexed as

CysteineSignal TransductionAnimalsArsenicalsDNAImmunity, InnateMembrane ProteinsMiceNucleotidyltransferasesArsenicalsCysteineDNAMembrane ProteinsNucleotidyltransferasesoxophenylarsinecysteine modificationinnate immunityphenylarsine oxideSTING agonist

Identifiers

PMID36575042
PMCPMC10721953
OpenAlexW4313184158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.